All In Biotech

Drug Trial Radar · NCT06898060

To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture

A Multicenter, Randomized, Open-label, Parallel Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture

Last checked: Nov 19, 2026Latest source record: Mar 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 282 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

282

Planned (sponsor's estimate)

Start

Jun 2025

Primary completion

May 2027

Study completion May 2027

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of QLG2128 in the treatment of postmenopausal women with osteoporosis and at high risk of fracture.

Conditions

  • Postmenopausal Women With Osteoporosis

Interventions

  • QLG2128Drug

    Recommended dosage is 80 μg subcutaneously once daily,52week

  • Teriparatide InjectionDrug

    Recommended dosage is 20μg subcutaneously once daily,52week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Bone Mineral Density (BMD) of Lumbar Spine From Baseline to 52 WeekTime frame: Baseline to 52 Week

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.